Yes, triazolam is a controlled substance. It is classified as a Schedule IV drug under the federal Controlled Substances Act, placing it in the same category as other benzodiazepines like diazepam and lorazepam. This classification means triazolam has a recognized medical use but carries a real potential for abuse and dependence.
What Schedule IV Means for You
The DEA’s scheduling system runs from Schedule I (highest restriction, no accepted medical use) down to Schedule V (lowest restriction). Schedule IV sits near the lower end, indicating a lower abuse potential compared to drugs like oxycodone (Schedule II) or ketamine (Schedule III), but enough risk that the government regulates how it’s prescribed, dispensed, and refilled.
In practical terms, Schedule IV status means triazolam requires a prescription from a licensed provider. Federal law limits you to five refills per prescription, and those refills must all happen within six months of the original date the prescription was written. After that window closes, or after five refills, your prescriber must write an entirely new prescription. You cannot call your pharmacy and simply request more.
Why Triazolam Is Regulated
Triazolam, sold under the brand name Halcion, is a benzodiazepine prescribed for short-term treatment of insomnia, typically 7 to 10 days. The FDA label states that use beyond two to three weeks requires a complete reevaluation. It works by enhancing the activity of GABA, a chemical messenger in the brain that slows nerve signaling, which is how it produces its sedative effect.
Several characteristics make triazolam a candidate for controlled status. It acts fast, reaching peak levels in the blood within two hours, and it clears the body quickly, with a half-life ranging from 1.5 to 5.5 hours. That rapid onset can make the drug feel rewarding, which increases the likelihood of misuse. Animal studies have shown that triazolam produces physical dependence after continued use, with a recognizable benzodiazepine withdrawal syndrome appearing when the drug is stopped after 85 to 100 days of daily dosing.
The FDA’s most prominent safety warning for Halcion, a boxed warning (the most serious type), addresses three risks directly: abuse and addiction, physical dependence and withdrawal, and dangerous interactions with opioids. Combining triazolam with opioid medications can cause profound sedation, respiratory depression, coma, and death.
Dependence and Withdrawal Risks
Physical dependence on triazolam can develop even when the drug is taken exactly as prescribed. The risk increases with higher doses and longer treatment duration. This is a key reason for the short recommended treatment window. Most adults are started at 0.25 mg taken at bedtime, with 0.125 mg sometimes sufficient for people with lower body weight. The maximum dose is 0.5 mg, reserved for patients who don’t respond to lower amounts. For older adults, the ceiling is 0.25 mg.
Stopping triazolam abruptly after regular use can trigger acute withdrawal reactions that the FDA describes as potentially life-threatening. Symptoms follow the pattern seen with other benzodiazepines: anxiety, agitation, sleep disturbance, tremors, and in severe cases, seizures. A gradual taper, where the dose is slowly reduced over time, is the standard approach to discontinuation. If you’ve been taking triazolam regularly and want to stop, your prescriber will typically create a tapering schedule rather than having you quit all at once.
Other Safety Concerns
Triazolam is known to cause anterograde amnesia, a type of memory impairment where you have difficulty forming new memories after taking the drug. This can mean waking up with no recollection of things you did or conversations you had after your dose. The risk is higher at larger doses.
The drug is also contraindicated with certain medications that interfere with the enzyme system your liver uses to break it down. Specific antifungal medications, certain HIV treatments, and some antidepressants can cause triazolam to build up to dangerous levels in the body. If you take any of these, triazolam is not an option.
Because of its short half-life, triazolam is less likely than longer-acting sleep medications to cause next-day grogginess. That same short duration, though, means it may not keep you asleep through the entire night if your insomnia involves waking up too early rather than difficulty falling asleep.
How Prescriptions Are Handled
Unlike Schedule II drugs (such as certain stimulants and opioids), Schedule IV prescriptions like triazolam can be called in or transmitted electronically by your prescriber. You don’t need a new paper prescription for each refill. However, many prescribers still write triazolam for limited quantities and short durations, reflecting both the FDA’s short-term use guidance and the drug’s dependence potential.
State laws sometimes impose additional restrictions beyond federal requirements. Some states limit the quantity dispensed per prescription or require prescribers to check a prescription drug monitoring program before writing a new script. If you’re unsure about the rules where you live, your pharmacist can clarify what applies to your specific situation.